# Iovance Biotherapeutics, Inc.: overview

IOVA · Nasdaq · CIK 1425205 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/iova.md) · [Financials](/companies/iova/financials.md) · [Filings](/companies/iova/filings.md) · [Insiders](/companies/iova/insiders.md)

Latest reported revenue: [$99.3m](/filings/0001104659-26-091716.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-091716).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [58.6](/filings/0001104659-25-107470.md) | [73.7 d](/filings/0001104659-26-018899.md) | [49.3](/filings/0001104659-26-056778.md) | [60.0](/filings/0001104659-26-091716.md) | [67.5](/filings/0001104659-25-107470.md) | [86.8 d](/filings/0001104659-26-018899.md) | [71.4](/filings/0001104659-26-056778.md) | [99.3](/filings/0001104659-26-091716.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(152.1%)](/filings/0001104659-25-107470.md) | [(117.5%) d](/filings/0001104659-26-018899.md) | [(245.8%)](/filings/0001104659-26-056778.md) | [(189.8%)](/filings/0001104659-26-091716.md) | [(140.7%)](/filings/0001104659-25-107470.md) | [(84.7%) d](/filings/0001104659-26-018899.md) | [(113.5%)](/filings/0001104659-26-056778.md) | [(52.3%)](/filings/0001104659-26-091716.md) |
| Net margin | % | [(142.7%)](/filings/0001104659-25-107470.md) | [(106.6%) d](/filings/0001104659-26-018899.md) | [(235.5%)](/filings/0001104659-26-056778.md) | [(186.2%)](/filings/0001104659-26-091716.md) | [(135.3%)](/filings/0001104659-25-107470.md) | [(82.9%) d](/filings/0001104659-26-018899.md) | [(110.7%)](/filings/0001104659-26-056778.md) | [(47.6%)](/filings/0001104659-26-091716.md) |
| Diluted EPS | $ per share | [(0.28)](/filings/0001558370-24-014905.md) | not reported | [(0.36)](/filings/0001104659-26-056778.md) | [(0.33)](/filings/0001104659-26-091716.md) | not reported | not reported | [(0.19)](/filings/0001104659-26-056778.md) | [(0.11)](/filings/0001104659-26-091716.md) |
| Free cash flow | $m | [(61.3) d](/filings/0001104659-25-107470.md) | [(77.5) d](/filings/0001104659-26-018899.md) | [(110)](/filings/0001104659-26-056778.md) | [(74.9) d](/filings/0001104659-26-091716.md) | [(89.5) d](/filings/0001104659-25-107470.md) | [(61.9) d](/filings/0001104659-26-018899.md) | [(78.7)](/filings/0001104659-26-056778.md) | [(66.3) d](/filings/0001104659-26-091716.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [1.2](/filings/0001104659-26-018899.md) | [164](/filings/0001104659-26-018899.md) | [264](/filings/0001104659-26-018899.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(38735.0%)](/filings/0001104659-26-018899.md) | [(240.9%)](/filings/0001104659-26-018899.md) | [(153.1%)](/filings/0001104659-26-018899.md) |
| Net margin | % | not reported | not reported | [(37345.4%)](/filings/0001104659-26-018899.md) | [(226.8%)](/filings/0001104659-26-018899.md) | [(148.4%)](/filings/0001104659-26-018899.md) |
| Diluted EPS | $ per share | [(2.23)](/filings/0001558370-24-002036.md) | [(2.49)](/filings/0001558370-25-001834.md) | [(1.89)](/filings/0001104659-26-018899.md) | [(1.28)](/filings/0001104659-26-018899.md) | [(1.09)](/filings/0001104659-26-018899.md) |
| Free cash flow | $m | [(266)](/filings/0001558370-24-002036.md) | [(313)](/filings/0001558370-25-001834.md) | [(384)](/filings/0001104659-26-018899.md) | [(364)](/filings/0001104659-26-018899.md) | [(336)](/filings/0001104659-26-018899.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/iova/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $153.7m | 36,957,681 |  | Added +5,877,176 |
| [MHR FUND MANAGEMENT LLC](/funds/1277742.md) | 2026-06-30 | $120.5m | 28,967,103 |  | Unchanged |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $101.8m | 24,478,268 |  | Added +7,030,160 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $79.1m | 19,010,697 |  | Added +5,323,264 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $75.7m | 18,204,248 |  | Added +1,586,511 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $59.9m | 14,388,999 |  | Added +2,688,155 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $43.0m | 10,324,826 |  | Added +1,752,228 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $35.5m | 8,525,919 |  | Reduced −888,373 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $26.9m | 6,460,449 |  | Added +3,814,747 |
| [Palo Alto Investors LP](/funds/1306923.md) | 2026-06-30 | $22.0m | 5,296,209 |  | Reduced −1,053,354 |

## Recent filings

[All 1,016 filings](/companies/iova/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 17:00 ET | [8-K](/filings/0001104659-26-120261.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-120261 |
| 2026-10-05 | 17:00 ET | [8-K](/filings/0001104659-26-113763.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-113763 |
| 2026-09-29 | 07:05 ET | [8-K](/filings/0001104659-26-111583.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-111583 |
| 2026-08-06 | 17:30 ET | [8-K](/filings/0001104659-26-092145.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-092145 |
| 2026-08-06 | 09:15 ET | [10-Q](/filings/0001104659-26-091716.md) | Quarterly report, period 2026-06-30 | 0001104659-26-091716 |
| 2026-08-06 | 07:05 ET | [8-K](/filings/0001104659-26-091619.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-091619 |
| 2026-07-02 | 17:01 ET | [8-K](/filings/0001104659-26-080409.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-080409 |
| 2026-06-10 | 17:01 ET | [8-K](/filings/0001104659-26-072408.md) | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-072408 |
| 2026-05-07 | 09:18 ET | [8-K](/filings/0001104659-26-056782.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-056782 |
| 2026-05-07 | 09:16 ET | [10-Q](/filings/0001104659-26-056778.md) | Quarterly report, period 2026-03-31 | 0001104659-26-056778 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-018899.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/76807f3c-10ce-4928-9e29-7e39d826db9c)

## About the filer

- CIK: 1425205
- Tickers: IOVA
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:02 ET. No prices; not investment advice.